Summary One component of decisions regarding hepatitis B virus (HBV) treatment simplification and expansion is the economic perspective. Literature was reviewed for studies which provide estimates for the economic impact of simplifying and expanding treatment eligibility. Eight published studies and four unpublished studies were included and all but one subset of one study found that […]
Summary The World Health Organization (WHO) has outlined a set of targets to achieve eliminating hepatitis C by 2030. In May 2022, Lithuanian health authorities initiated a hepatitis C virus (HCV) screening program to start working towards elimination. In the program, bonus was given to general practitioners (GPs) to promote and conduct anti-HCV tests for […]
Summary The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, the HBV prevalence in Western countries, where the historical prevalence is low and highly impacted by immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate of HBV prevalence and identify key […]
Summary Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most of the infected individuals in the United States remain undiagnosed and untreated. There is a need to understand more completely the economic and disease burden impact of removing treatment restrictions and increasing diagnosis and treatment. […]
Summary Chronic hepatitis B infection (defined as sustained detection of hepatitis B virus [HBV] surface antigen [HBsAg] protein in serum) is a leading cause of cirrhosis, hepatocellular carcinoma and liver-related deaths. A situation analysis carried out by the Swiss Federal Office of Public Health estimated the HBsAg prevalence in Switzerland to be 0.53% (95% CI: […]
Resumen Menos de la mitad de los lactantes del mundo tienen acceso a la dosis de nacimiento de la vacuna contra la hepatitis B (VHB), que previene la transmisión de madre a hijo de esta enfermedad y el consiguiente cáncer de hígado. Ha llegado el momento de ampliar el acceso a la vacuna para los lactantes nacidos en entornos de bajos recursos. Lea el informe completo
Resumen El tratamiento antiviral en pacientes con hepatitis B crónica (HBC) puede reducir el riesgo de carcinoma hepatocelular (HCC) y muerte. Sin embargo, solo el 2,2% de los pacientes con HBC reciben tratamiento antiviral a nivel mundial. La complejidad y el rigor de las guías de práctica clínica actuales pueden limitar la expansión de la cobertura del tratamiento para la HBC. Examinamos el impacto de la expansión del tratamiento […]
Summary Background Treatment for infection with hepatitis C virus (HCV) during pregnancy has not yet been approved; however, interventions specifically targeting women, especially those of childbearing age (15–49 years), could prevent vertical transmission and community spread. To assess the impact of such interventions, improved prevalence estimates in this group are needed. We aimed to estimate […]
Spanish 
English 
French 
Russian 
Arabic